Sellas Life Sciences is trading now 4.08% down at $11.52 as investors await its August 11, 2026, earnings report.
- No new company-specific announcement was identified on August 10, 2026, and the investor-relations page shows no dated release explaining the decline.
- The move follows several strong sessions, with investors also awaiting further updates on the pivotal REGAL trial.
- Broader markets are mixed, so macro sentiment does not clearly explain the drop.